文献速递颈动脉与弓上血管

血管外科学会血管质量倡议颈动脉支架置入术当代基准

Society for Vascular Surgery Vascular Quality Initiative contemporary benchmarks: Carotid artery stenting.
PubMed 文献 · J Vasc Surg · 2026-09-23

基于VQI 2011–2024年119,240例颈动脉支架置入术(CAS)数据,以2021–2024年78,997例为当代基准,比较经颈动脉血运重建(TCAR)与经股动脉CAS(TFCAS)。TCAR占73.6%,其院内卒中、死亡和主要不良心血管事件率均低于TFCAS,症状性患者1年同侧卒中亦更低;

要点

  • 2021–2024年VQI中TCAR占CAS的73.6%,已成为主要术式。
  • TCAR较TFCAS院内卒中、死亡及MACE更低,症状性与无症状患者一致。
  • 症状性患者TCAR1年同侧卒中更低(5.6% vs 8.5%),无症状者无显著差异。

核心结论

  • 当代VQI实践中,无论症状状态,TCAR较TFCAS与更低的未校正院内及1年卒中和死亡率相关。

研究设计与样本

  • 分析VQI 2011–2024年全部CAS手术,共119,240例,来自821个中心、3,991名医师。
  • 当代基准分析限定2021–2024年78,997例,按症状状态和术式(TCAR vs TFCAS)分层。

主要发现

  • 院内卒中:无症状TCAR 0.9% vs TFCAS 1.4%,症状性1.8% vs 2.8%。
  • 院内死亡:无症状0.3% vs 0.7%,症状性0.5% vs 1.8%;MACE:无症状1.5% vs 2.1%,症状性2.5% vs 4.4%(均P < .05)。
  • 1年同侧卒中:症状性TCAR 5.6% vs TFCAS 8.5%(P < .001),无症状2.8% vs 3.4%(P = .054)。
  • 1年死亡:无症状3.0% vs 4.5%,症状性5.0% vs 7.6%(均P < .001)。

临床怎么用

  • 可将上述当代基准用于CAS术式选择与质量评估,TCAR在卒中和死亡方面表现更优。
  • 需关注CMS政策变化对TCAR与TFCAS使用格局的影响,并持续通过登记研究监测。

局限性

  • 结局为未校正比较,原文未报告多因素校正结果。
  • 1年结局仅基于有长期随访数据的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Carotid artery stenting (CAS) utilization and indications have evolved substantially with the introduction of transcarotid artery revascularization (TCAR), recent regulatory expansion, and renewed attention following contemporary trial data. We sought to establish contemporary real-world benchmark outcome rates for CAS and characterize temporal trends and modality adoption within the Vascular Quality Initiative (VQI). METHODS: We analyzed all CAS procedures recorded in the VQI from 2011 to 2024. Contemporary benchmark analyses were restricted to procedures performed from 2021 to 2024, selected to reflect recent practice following the coronavirus disease 2019 pandemic and the maturation of TCAR adoption, and stratified by symptomatic status and modality [TCAR vs transfemoral CAS (TFCAS)]. Primary outcomes included in-hospital stroke, death, myocardial infarction, and major adverse cardiovascular events. One-year ipsilateral stroke and mortality were assessed among patients with available long-term follow-up data. Temporal trends in utilization were evaluated across the full study period and in relation to regulatory milestones, outcomes were compared by operator volume and physician-level TCAR adoption patterns were examined among Physicians with an established pre-2016 TFCAS practice. RESULTS: A total of 119,240 CAS procedures were identified across 821 centers and 3991 physicians, including 78,997 performed during the 2021 to 2024 benchmark period. TCAR comprised 73.6% of procedures performed during 2021 to 2024. In-hospital stroke rates were lower with TCAR than TFCAS in both asymptomatic (0.9% vs 1.4%) and symptomatic patients (1.8% vs 2.8%), as were death (0.3% vs 0.7% asymptomatic; 0.5% vs 1.8% symptomatic) and major adverse cardiovascular events (1.5% vs 2.1% asymptomatic; 2.5% vs 4.4% symptomatic; all P < .05). One-year ipsilateral stroke was lower after TCAR in symptomatic patients (5.6% vs 8.5%; P < .001) but did not differ significantly in asymptomatic patients (2.8% vs 3.4%; P = .054); 1-year mortality was lower after TCAR in both strata (3.0% vs 4.5% asymptomatic; 5.0% vs 7.6% symptomatic; both P < .001). In 2016, TCAR accounted for 7% of CAS procedures and TFCAS 93%, shifting to 76% and 24% respectively by 2023; annual TFCAS volume remained relatively stable through 2020 before increasing thereafter. Following the October 2023 Centers for Medicare and Medicaid Services National Coverage Determination extending standard-risk coverage to both modalities, TCAR volume fell 11.5% (P = .008) and then declined 0.6% per month through December 2024, whereas TFCAS volume rose 11.2% (P = .026). Among 97 physicians with established pre-2016 TFCAS practice who subsequently adopted TCAR and remained active through 2022 to 2024, TCAR accounted for 85% of CAS volume by 2024, with lower pre-existing TFCAS volume associated with faster TCAR adoption. CONCLUSIONS: In contemporary VQI practice, TCAR is associated with lower unadjusted in-hospital and 1-year stroke and mortality rates compared with TFCAS regardless of the symptomatic status. TCAR adoption grew rapidly from 2016 through 2023 before declining following the October 2023 Centers for Medicare and Medicaid Services policy change. As CAS utilization expands in the setting of evolving policy and trial evidence, these findings provide contemporary real-world benchmarks and underscore the need for continued registry-based surveillance.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Malas M, Nakhaei P, Ochoa Chaar CI, et al. Society for Vascular Surgery Vascular Quality Initiative contemporary benchmarks: Carotid artery stenting. J Vasc Surg. 2026. PMID: 42772611. doi:10.1016/j.jvs.2026.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。